Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson's disease and overlap with other neurodegenerative disorders.

Homann J., Smith AG., Morgan S., Frick EA., Liu F., Viallon V., Maurya R., Korologou-Linden R., Dobricic V., Ohlei O., Deecke L., Hajizadah F., Zhao Y., Artaud F., Smith-Byrne K., Kolijn PM., Huerta JM., Winter N., Guevara M., Jimenez-Zabala A., Sánchez MJ., Trobajo-Sanmartín C., Cabrera-Castro N., Vinagre A., Petrova D., Sieri S., Key TJ., Wareham N., Kaaks R., Travis RC., Hahn T., Baker S., Kelly SM., Vermeulen R., Peters S., Masala G., Sacerdote C., Finkel N., Global Neurodegeneration Proteomics Consortium (GNPC) ., Elbaz A., Hess M., Katzke V., Bertram L., Gudnason V., Robinson O., Chen H., Middleton L., Winchester LM., Tzoulaki I., Gudmundsdottir V., Walker KA., Ferrari P., Riboli E., Gunter MJ., Lill CM.

DOI

10.1101/2025.07.30.25332433

Type

Preprint

Publication Date

2025-07-30T00:00:00+00:00

Keywords

EPIC, Parkinson’s disease, SomaLogic, aptamers, neurodegeneration, prediction, protein risk score, proteomics

Permalink More information Close